ACRS - Aclaris Therapeutics GAAP EPS of -$0.31 beats by $0.05 revenue of $1.53M misses by $0.08M August, 03 2022 07:57 AM Aclaris Therapeutics Inc. Aclaris Therapeutics press release ( NASDAQ: ACRS ): Q2 GAAP EPS of -$0.31 beats by $0.05 . Revenue of $1.53M (-15.9% Y/Y) misses by $0.08M . For further details see: Aclaris Therapeutics GAAP EPS of -$0.31 beats by $0.05, revenue of $1.53M misses by $0.08M